Medical/Pharmaceuticals
Microbio Co., Ltd. (4128) Announces Promising Results of "MS-20" in Combination with Keytruda for Stage IIIb/IV Non-Small Cell Lung Cancer
CUPERTINO, Calif., Dec. 16, 2024 /PRNewswire/ -- Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the object...
2024-12-17 02:05
1017
Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers
CAMBRIDGE, Mass., Dec. 16, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM ), today announced a research collaboration and license agreement to discover next-generation T-cell engagers ("TCEs") with Candid Therapeutics, ...
2024-12-16 20:03
836
Fangzhou Inc. Garners Prestigious "Most Valued Pharmaceutical & Healthcare Enterprise" Award
SHENZHEN, China, Dec. 16, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, was honored with a "Most Valued Pharmaceutical & Healthcare Enterprise" award at the grand "9th Zhitong Finance Capital Market Summit and Listed Compan...
2024-12-16 18:13
1157
China Pharma Announces the Entry of "At-The-Market" Equity Offering
HAIKOU, China, Dec. 13, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") under which...
2024-12-13 21:00
2822
Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101
* Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerative Colitis (UC) * A Phase Ib Study of AC-101 for Ulcerative Colitis (UC) has been initiated in China * AC-101 demonstrated a favorable safety and PK/PD profile in healthy volunteers in Phase Ia ...
2024-12-13 12:57
1233
Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS
PRINCETON, N.J. and SUZHOU, China, Dec. 12, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, ann...
2024-12-13 08:00
1317
2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
YANTAI, China, Dec. 12, 2024 /PRNewswire/ -- On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS),RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data from ...
2024-12-13 07:20
1434
New Lunit Study Demonstrates Universal AI Model for Analysis of Immunohistochemistry Images
Research in npj Precision Oncology highlights multi-cohort training approach and accurate analysis of unseen immunohistochemistry data SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, toda...
2024-12-12 22:08
1627
CureGene Received Clinical Trial Approval in China for CG-0255 for Injection - A Novel Antiplatelet Therapy
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval of its Clinical Trial Application by theChina's...
2024-12-12 21:00
1307
Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.
CHONGQING, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Porton Pharma
Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life
Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences").
2024-12-12 21:00
1378
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...
2024-12-12 21:00
1631
KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigational New Drug (IND) Application for AND017 for Clinical Trial in Sickle Cell Disease (SCD)
SAN FRANCISCO, Dec. 12, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that preclinical...
2024-12-12 16:25
1239
RSNA 2024 Spotlight: Careverse Leads the New Trend in Medical AI
CHICAGO, Dec. 12, 2024 /PRNewswire/ -- From December 1st to 5th, 2024, RSNA 2024—the largest and most future-oriented top medical event in the global radiology community, was held inChicago. At this conference, Careverse officially made its debut, exhibiting in the AI Showcase area, sharing its ...
2024-12-12 16:04
939
Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024
LOS ANGELES, Dec. 11, 2024 /PRNewswire/ -- Laekna (2105.HK) today announced that the company will present an internally discovered preclinical candidate at the 2024 San Antonio Breast Cancer Symposium (SABCS) onDecember 13, 2024. The presentation will feature preclinical characterization of LAE11...
2024-12-12 08:30
1122
Nature Biotechnology | Generative Chemistry Enables Insilico to Develop Gut-Restricted PHD Inhibitors Promising for Intestinal Mucosal Barrier Repair and Immunomodulation
* The study presents the journey of designing and optimizing novel gut-restricted PHD inhibitors using the comprehensive generative chemistry engine Chemistry42. * From initiation to preclinical candidate nomination, the program spanned only 12 months, during which approximately 115 molecules...
2024-12-11 22:25
1284
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
Sunvozertinib, as a single agent, demonstrated promising antitumor activity and favorable safety profile in heavily pretreated patients with EGFR-mutated NSCLC who had developed resistance to EGFR TKI treatment SHANGHAI, Dec. 11, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical compa...
2024-12-11 18:05
1392
Syrebo Unveils Innovative Rehab Robots at MEDICA 2024: A Spectacular Showcase!
SHANGHAI, Dec. 11, 2024 /PRNewswire/ -- On November 11, Syrebo showcased
several innovative rehabilitation robot products at MEDICA 2024 in Düsseldorf.
Its upper limb rehabilitation robot, BCI rehabilitation robot, and newly
launched home rehabilitation robot attracted attention.
2024-12-11 14:00
1021
Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment
DOVER, Del. and EPALINGES, Switzerland, Dec. 10, 2024 /PRNewswire/ -- Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Ach...
2024-12-11 11:04
1133
【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies
NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, ...
2024-12-10 23:00
1475
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...
2024-12-10 21:26
1360
Week's Top Stories
Most Reposted
PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS
[Picked up by 323 media titles]
2024-12-19 13:41
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
[Picked up by 305 media titles]
2024-12-19 17:56
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 305 media titles]
2024-12-20 16:25
ADA Acquires Customore, Launching the Most Advanced Intelligent Commerce Solution for the CPG Industry
[Picked up by 296 media titles]
2024-12-17 11:00
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 296 media titles]
2024-12-20 18:11
Most Read
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
2024-12-19 17:56
4151
ADA Acquires Customore, Launching the Most Advanced Intelligent Commerce Solution for the CPG Industry
2024-12-17 11:00
4103
PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS
2024-12-19 13:41
3874
Dhaka Court Dismisses Allegations Against Nagad Founder Tanvir A Mishuk
2024-12-16 18:32
3814
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
2024-12-20 18:11
3642